Reuters: Health
GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38% in a late-stage study in cancer patients.
GlaxoSmithKline's cancer therapy cuts risk of disease progression or death by 38%
GlaxoSmithKline's cancer therapy cuts risk of disease progression or death by 38%
Reuters: Health
GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38% in a late-stage study in cancer patients.
Reuters: Health
GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38% in a late-stage study in cancer patients.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment